Skip to main content
. 2023 Jun 21;11(6):e007068. doi: 10.1136/jitc-2023-007068

Figure 2.

Figure 2

Characterization of bispecific peptide targeting CD24/PD-L1. (A) Blocking activities of optimized peptides. (B) In vitro blocking activity of CSBP on the human CD24/hSiglec-10 interaction as measured by flow cytometry. (C) In vitro binding affinity of CSBP on human CD24 as measured by MST. (D) In vitro blocking activity of CSBP on the human PD-1/PD-L1 interaction as measured by flow cytometry. (E) Binding affinity of CSBP on human PD-L1 as measured by MST. (F) Representative HPLC analysis of CSBP hydrolysis in 10% human serum. (G) The residual peptide time-dependent curve. Data are presented as means±SEM. BP, blocking peptide; CSBP, CD24/Siglec-10 blocking peptide; HPLC, high performance liquid chromatography; MST, microscale thermophoresis; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1.